EphA4 is a prognostic factor in gastric cancer

BMC Clinical Pathology

Table 3 Correlations between the expression of EphA2, EphA4, and ephrinA1 and clinicopathological factors

		EphA2			EphA4			ephrinA1
		low	high	p	low	high	p	low	high	p
	n	77	145		111	111		107	115
Age
<70	142	53	89	0.27	75	67	0.26	72	70	0.32
≥70	80	24	56	0.27	36	44	0.26	35	45	0.32
Gender
female	54	17	37	0.57	32	22	0.12	29	25	0.35
male	168	60	108	0.57	79	89	0.12	78	90	0.35
Main location
middle or lower	177	66	111	0.11	89	88	0.87	92	85	0.025
upper	45	11	34	0.11	22	23	0.87	15	30	0.025
WHO pathological type
differentiated	107	35	72	0.55	54	53	0.89	48	59	0.34
undifferentiated	115	42	73	0.55	57	58	0.89	59	56	0.34
Depth of invasion
T1/2	118	59	59	<0.001	85	33	<0.001	69	49	0.001
T3/4	104	18	86	<0.001	26	78	<0.001	38	66	0.001
Lymphatic invasion
negative	69	35	34	0.001	51	18	<0.001	47	22	<0.001
positive	153	42	111	0.001	60	93	<0.001	60	93	<0.001
Venous invasion
negative	73	39	34	0.001	55	18	<0.001	52	21	<0.001
positive	149	38	111	0.001	56	93	<0.001	55	94	<0.001
Lymph node metastasis
negative (N0)	114	54	60	0.001	77	37	<0.001	65	49	0.007
positive (N1/2/3)	108	23	85	0.001	34	74	<0.001	42	66	0.007
Stage
I / II	142	66	76	<0.001	95	47	<0.001	80	62	0.001
III/IV	80	11	69	<0.001	16	64	<0.001	27	53	0.001
Distant metastasis or recurrence
negative	152	69	83	<0.001	99	53	<0.001	81	71	0.025
positive	70	8	62		12	58		26	44

ISSN: 1472-6890